• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The mechanisms of minocycline in alleviating ischemic stroke damage and cerebral ischemia-reperfusion injury
Eur J Pharmacol. 2023 Jul 6:175903. doi: 10.1016/j.ejphar.2023.175903. Online ahead of print.ABSTRACTStroke is a group of diseases resulting from cerebral vascular rupture or obstruction and subsequent brain blood circulation disorder, leading to rapid neurological deficits. Ischemic stroke accounts for the majority of all stroke cases. The current treatments for ischemic stroke mainly include t-PA thrombolytic therapy and surgical thrombectomy. However, these interventions aimed at recanalizing cerebral vessels can paradoxically lead to ischemia-reperfusion injury, which exacerbates the severity of brain damage. Minocycli...
Source: European Journal of Pharmacology - July 8, 2023 Category: Drugs & Pharmacology Authors: Kemeng Zhao Pengwei Wang Xiaoguang Tang Na Chang Haonan Shi Longfei Guo Bingyi Wang Pengfei Yang Tiantian Zhu Xinghua Zhao Source Type: research

Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline.
Authors: Blacker DJ, Prentice D, Alvaro A, Bates TR, Bynevelt M, Kelly A, Kho LK, Kohler E, Hankey GJ, Thompson A, Major T Abstract Haemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT in rodents with stroke treated with tissue plasminogen activator (tPA). The West Australian Intravenous Minocycline and TPA Stroke Study (WAIMATSS) aims to determine the safety and efficacy ...
Source: Stroke Research and Treatment - December 2, 2014 Category: Neurology Tags: Stroke Res Treat Source Type: research

Clinical Trials in Acute Ischemic Stroke
Abstract Acute ischemic stroke (AIS) is a major cause of mortality and disability and remains a serious and significant global health problem. The development of neurovascular protectants to treat AIS successfully has been beset by disappointments and setbacks. Many promising candidates have lacked significant pleiotropic protective activity for brain tissue and cerebral blood vessels in clinical trials, while those with protective activity have had poor bioavailability or high toxicity. Moreover, the majority of agents did not confer significant neurovascular protection or clinical efficacy, as measured by standa...
Source: CNS Drugs - August 27, 2014 Category: Neurology Source Type: research

Minocycline Repurposing in Critical Illness: Focus on Stroke.
Abstract Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models a...
Source: Current Topics in Medicinal Chemistry - September 20, 2013 Category: Chemistry Authors: Vivian Liao T, C Forehand C, Hess DC, Fagan SC Tags: Curr Top Med Chem Source Type: research

Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes
The objective of the present study was to determine the effects of acute manipulation of potential targets for vascular protection [i.e., NF-B, peroxynitrite, and matrix metalloproteinases (MMPs)] on vascular injury and functional outcome in a diabetic model of cerebral ischemia. Ischemia was induced by middle cerebral artery occlusion in control and type 2 diabetic Goto-Kakizaki rats. Treatment groups received a single dose of the peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato iron (III), the nonspecific NF-B inhibitor curcumin, or the broad-spectrum MMP inhibitor minocycline at re...
Source: AJP: Heart and Circulatory Physiology - March 15, 2013 Category: Cardiology Authors: Kelly-Cobbs, A. I., Prakash, R., Li, W., Pillai, B., Hafez, S., Coucha, M., Johnson, M. H., Ogbi, S. N., Fagan, S. C., Ergul, A. Tags: VASCULAR BIOLOGY AND MICROCIRCULATION Source Type: research

Targets of Vascular Protection in Acute Ischemic Stroke Differ in Type 2 Diabetes.
The objective of the current study was to determine the effects of acute manipulation of potential targets for vascular protection (i.e., NFkB, peroxynitrite, and matrix metalloproteinases) on vascular injury and functional outcome in a diabetic model of cerebral ischemia. Ischemia was induced by middle cerebral artery occlusion in control and type 2 diabetic Goto-Kakizaki rats. Treatment groups received a single dose of peroxynitrite decomposition catalyst FeTPPs,a non-specific NFkB inhibitor curcumin, or a broad-spectrum matrix metalloproteinase (MMP) inhibitor minocycline at reperfusion. Post-stroke infarct volume, edem...
Source: American Journal of Physiology. Heart and Circulatory Physiology - January 18, 2013 Category: Physiology Authors: Kelly-Cobbs AI, Prakash R, Li W, Pillai B, Hafez S, Coucha M, Johnson MH, Ogbi SN, Fagan SC, Ergul A Tags: Am J Physiol Heart Circ Physiol Source Type: research